马丽媛,王增武,樊静,胡盛寿

• 1:国家心血管病中心北京协和医学院中国医学科学院阜外医院

摘要(Abstract)：

2019年农村、城市心血管病（CVD）分别占死因的46.74%和44.26%。每5例死亡中就有2例死于CVD。推算CVD现患人数3.3亿，其中脑卒中1 300万，冠心病1 139万，心力衰竭890万，肺源性心脏病500万，心房颤动487万，风湿性心脏病250万，先天性心脏病200万，下肢动脉疾病4 530万，高血压2.45亿。我国正面临人口老龄化和代谢危险因素持续流行的双重压力，CVD负担仍将持续增加，这对我国CVD防治策略和医疗资源配置提出了新的需求，包括通过一级预防以减少发病人数，增加心血管急重症救治的医疗资源配置，提供康复和二级预防的医疗服务以降低大量CVD存活患者复发、再住院和失能的风险。中国患有高血压、血脂异常和糖尿病的人数已经高达数亿，多数情况下，血压、血脂及血糖水平升高隐匿发生，常常在检出时已经导致血管病变，甚至已发生心肌梗死、脑卒中等严重事件，应加强预防高血压、血脂异常、糖尿病、肥胖和吸烟等零级预防工作，也应加强心血管健康状态的评估和早期病理变化的防治研究工作。

关键词(KeyWords)： 心血管病;流行病学;健康影响因素;危险因素;患病率;死亡率;社区防治;康复;基础研究;器械研发

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 马丽媛,王增武,樊静,胡盛寿

参考文献(References)：

• [1] Zhou MG, Wang HD, Zeng XY, et al. Mortality, morbidity,and risk factors in China and its provinces, 1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet,2019, 394(10204):1145-1158.
• [2]中国疾病预防控制中心. 2018年中国成人烟草调查报告[M].北京：人民卫生出版社，2020.
• [3]庞元捷，余灿清，郭彧，等.中国成年人行为生活方式与主要慢性病的关联——来自中国慢性病前瞻性研究的证据[J].中华流行病学杂志，2021, 42(3):369-375.
• [4] Zhang JG, Wang ZH, Du WW, et al. Twenty-fi ve-year trends in dietary patterns among Chinese adults from 1991 to 2015[J].Nutrients, 2021, 13(4):1327.
• [5]毕小艺，李荔，杨媞媞，等.中国农村营养改善计划地区2019年学生零食消费及影响因素[J].中国学校卫生，2021, 42(3):329-333.
• [6]琚腊红，于冬梅，郭齐雅，等. 2015年中国18~59岁居民在外就餐行为及其对肥胖的影响[J].卫生研究，2021, 50(3):395-400.
• [7]姚业成，宫伟彦，宋超，等. 2010~2012年中国成年居民在外就餐行为分析[J].营养学报，2019, 41(1):10-14.
• [8]朴玮，赵丽云，房红芸，等.中国18岁及以上成人饮酒行为现况[J].中国食物与营养，2021, 27(10):15-19.
• [9] Han YT, Hu YZ, Yu CQ, et al. Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study[J].Eur Heart J, 2021, 42(34):3374-3384.
• [10] Neal B, Wu YF, Feng XX, et al. Ef fect of salt substitution on cardiovascular events and death[J]. N Engl J Med, 2021,385(12):1067-1077.
• [11] Strain T, Brage S, Sharp SJ, et al. Use of the prevented fraction for the population to determine deaths averted by existing prevalence of physical activity:a descriptive study[J]. Lancet Glob Health, 2020, 8(7):e920-e930.
• [12] Cao JH, Eshak ES, Liu KY, et al. An age-period-cohort analysis of stroke mortality attributable to low physical activity in China and Japan:data from the GBD study 1990-2016[J]. Sci Rep, 2020, 10(1):6525.
• [13] Liu Q, Liu FC, Huang KY, et al. Beneficial effects of moderate to vigorous physical activity on cardiovascular disease among Chinese adults[J]. J Geriatr Cardiol, 2020, 17(2):85-95.
• [14] Bennett DA, Du H, Clarke R, et al. Association of physical activity with risk of major cardiovascular diseases in Chinese men and women[J]. JAMA Cardiol, 2017, 2(12):1349-1358.
• [15]国家卫生健康委员会疾病预防控制局.中国居民营养与慢性病状况报告（2020）[M].北京，人民卫生出版社，2022.
• [16] Mu L, Liu J, Zhou G, et al. Obesity prevalence and risks among Chinese adults：fi ndings from the China PEACE million persons project, 2014-2018[J]. Circ Cardiovasc Qual Outcomes, 2021, 14(6):e007292.
• [17] Wang YF, Zhao L, Gao LW, et al. Health policy and public health implications of obesity in China[J]. Lancet Diabetes Endocrinol, 2021, 9(7):446-461.
• [18] Chen Z, Jiang S, Wang YF, et al. Pharmacoeconomics of obesity in China:a scoping review[J]. Expert Rev Pharmacoecon Outcomes Res, 2021, 21(2):173-181.
• [19] Zhao D, Wu Z, Zhang H, et al. Somatic symptoms vary in major depressive disorder in China[J]. Compr Psychiatry,2018, 87:32-37.
• [20] Wang ZW, Chen Z, Zhang LF, et al. Status of hypertension in China:results from the China hypertension survey 2012-2015[J].Circulation, 2018, 137(22):2344-2356.
• [21]张梅，吴静，张笑，等. 2018年中国成年居民高血压患病与控制状况研究[J].中华流行病学杂志，2021, 42(10):1780-1789.
• [22] Zhang WL, Zhang SY, Deng Y, et al. Trial of intensive blood-pressure control in older patients with hypertension[J].N Engl J Med, 2021, 385(14):1268-1279.
• [23] Xie X, He T, Kang J, et al. Cost-ef fectiveness analysis of intensive hypertension control in China[J]. Prev Med, 2018,111:110-114.
• [24] Xu HQ, Li YP, Shang XW, et al. Ef fect of comprehensive interventions including nutrition education and physical activity on high blood pressure among children:evidence from schoolbased cluster randomized control trial in China[J]. Int J Environ Res Public Health, 2020, 17(23):8944.
• [25] Song PK, Man QQ, Li H, et al. Trends in lipids level and dyslipidemia among Chinese adults, 2002-2015[J]. Biomed Environ Sci, 2019, 32(8):559-570.
• [26] NCD Risk Factor Collaboration(NCD-RisC). Repositioning of the global epicentre of non-optimal cholesterol[J]. Nature,2020, 582(7810):73-77.
• [27]李苏宁，张林峰，王馨，等. 2012~2015年我国≥35岁人群血脂异常状况调查[J].中国循环杂志，2019, 34(7):681-687.
• [28] Opoku S, Gan Y, Fu WN, et al. Prevalence and risk factors for dyslipidemia among adults in rural and urban China:findings from the China national stroke screening and prevention project(CNSSPP)[J]. BMC Public Health, 2019, 19(1):1500.
• [29] Zhang M, Deng Q, Wang L, et al. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults:a nationally representative survey of 163, 641adults[J]. Int J Cardiol, 2018, 260:196-203.
• [30]赵旺，叶平，胡大一，等.根据《中国成人血脂异常防治指南（2016年修订版）》再分析DYSIS-China横断面调查[J].中国心血管杂志，2020, 25(1):55-61.
• [31] Xing YY, Liu J, Hao YC, et al. Prehospital statin use and lowdensity lipoprotein cholesterol levels at admission in acute coronary syndrome patients with history of myocardial infarction or revascularization:findings from the improving care for cardiovascular disease in China(CCC)project[J]. Am Heart J, 2019, 212:120-128.
• [32]邢月妍，刘静，刘军，等. 75岁及以上老年急性冠状动脉综合征住院患者他汀使用现状及低密度脂蛋白胆固醇水平[J].中华心血管病杂志，2019, 47(5):351-359.
• [33]宋永健，杜鑫，郑梦伊，等.低密度脂蛋白胆固醇累积暴露对新发急性心肌梗死影响的前瞻性队列研究[J].中国循环杂志，2020, 35(3):246-253.
• [34] Sun L, Clarke R, Bennett D, et al. Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults[J]. Nat Med, 2019, 25(4):569-574.
• [35] Wang M, Liu J, Bellows BK, et al. Impact of China’s low centralized medicine procurement prices on the cost-ef fectiveness of statins for the primary prevention of atherosclerotic cardiovascular disease[J]. Glob Heart, 2020, 15(1):43.
• [36] Li YZ, Teng D, Shi XG, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association:national cross sectional study[J]. BMJ, 2020, 369:m997.
• [37] Gong QH, Zhang P, Wang JP, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance:30-year results of the Da Qing diabetes prevention outcome study[J]. Lancet Diabetes Endocrinol, 2019, 7(6):452-461.
• [38] Ma J, Wan X, Wu B. The cost-effectiveness of lifestyle interventions for preventing diabetes in a health resource-limited setting[J]. J Diabetes Res, 2020,2020:7410797.
• [39] Jin HY, Zhou JY, Wu CK. Prevalence and health correlates of reduced kidney function among community-dwelling Chinese older adults:the China Health and Retirement Longitudinal Study[J]. BMJ Open, 2020, 10(12):e042396.
• [40] Zhang L, Zhao MH, Zuo L, et al. China Kidney Disease Network(CK-NET)2016 Annual Data Report[J]. Kidney Int Suppl(2011), 2020, 10(2):e97-e185.
• [41] Li YR,Zhao LY,Yu DM,et al.Metabolic syndrome prevalence and its risk factors among adults in China:a nationally representative cross-sectional study[J].PLoS One,2018,13(6):e0199293.
• [42] Liang F, Xiao Q, Huang K, et al. The 17-y spatiotemporal trend of PM2.5 and its mortality burden in China[J]. Proc Natl Acad Sci U S A, 2020, 117(41):25601-25608.
• [43] Liu C, Yin P, Chen R, et al. Ambient carbon monoxide and cardiovascular mortality:a nationwide time-series analysis in 272 cities in China[J]. Lancet Planet Health, 2018, 2(1):e12-e18.
• [44] Chen R, Yin P, Meng X, et al. Fine particulate air pollution and daily mortality. a nationwide analysis in 272 Chinese cities[J].Am J Respir Crit Care Med, 2017, 196(1):73-81.
• [45] Chen R, Yin P, Meng X, et al. Associations between ambient nitrogen dioxide and daily cause-specific mortality:evidence from 272 Chinese cities[J]. Epidemiology, 2018, 29(4):482-489.
• [46] Chen R, Yin P, Meng X, et al. Associations between coarse particulate matter air pollution and cause-specific mortality:a nationwide analysis in 272 Chinese cities[J]. Environ Health Perspect, 2019, 127(1):17008.
• [47] Yu K, Lv J, Qiu G, et al. Cooking fuels and risk of all-cause and cardiopulmonary mortality in urban China:a prospective cohort study[J]. Lancet Glob Health, 2020, 8(3):e430-e439.
• [48] Hou L, Chen B, Ji Y, et al. China CDC in action–hypertension prevention and control[J]. China CDC Weekly,2020, 2(40):783-786.
• [49]国家卫生健康委员会.中国卫生健康统计年鉴2020[M].北京：中国协和医科大学出版社，2020.
• [50] Xu HY, Yang YJ, Wang CS, et al. Association of hospitallevel dif ferences in care with outcomes among patients with acute ST segment elevation myocardial infarction in China[J]. JAMA Netw Open, 2020, 3(10):e2021677.
• [51] Atkins ER, Du X, Wu Y, et al. Use of cardiovascular prevention treatments after acute coronary syndrome in China and associated factors[J]. Int J Cardiol, 2017, 241:444-449.
• [52] Song JL, Murugiah K, Hu S, et al. Incidence, predictors,and prognostic impact of recurrent acute myocardial infarction in China[J]. Heart, 2020, 107(4):313-318.
• [53]赵延延，杨进刚，许浩博，等.中国医院急性ST段抬高型心肌梗死医疗质量与住院死亡率的相关性分析[J].中国循环杂志，2019, 34(5):437-443.
• [54]国家心血管病医疗质量控制中心.《2021年中国心血管病医疗质量报告》概要[J].中国循环杂志，2021, 36(11):1041-1064.
• [55] Hu Z, Chen SP, Du JZ, et al. An in-hospital mortality risk model for patients undergoing coronary artery bypass grafting in China[J]. Ann Thorac Surg,2020, 109(4):1234-1242.
• [56] GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019:a systematic analysis for the Global Burden of Disease Study 2019[J].Lancet Neurol, 2021, 20(10):795-820.
• [57] Gu M, Hu Y, Hua W, et al. Visualization of tricuspid valve annulus for implantation of His bundle pacing in patients with symptomaticbradycardia[J]. J Cardiovasc Electrophysiol,2019, 30(10):2164-2169.
• [58] Wang ZW, Chen Z, Wang X, et al. The disease burden of atrial fi brillation in China from a national cross-sectional survey[J].Am J Cardiol, 2018, 122(5):793-798.
• [59] Guo J, Guan T, Fan S, et al. Underuse of oral anticoagulants in patients with ischemic stroke and atrial fi brillation in China[J].Am J Cardiol, 2018, 122(12):2055-2061.
• [60] Liu Y, Zhan X, Xue Y, et al. Incidence and outcomes of cerebrovascular events complicating catheter ablation for atrial fi brillation[J]. Europace, 2016, 18(9):1357-1365.
• [61]戈海延，李小梅，江河，等.儿童先天性长QT综合征5 8例临床特征及治疗分析[J].中华儿科杂志，2019, 57(4):272-276.
• [62] Jia PL, Wang YB, Fu H, et al. Postmortem analysis of 4mutation hotspots of KCNQ1, KCNH2, and SCN5A genes in sudden unexplained death in southwest of China[J]. Am J Forensic Med Pathol, 2018, 39(3):218-222.
• [63] Yang Y, Wang ZW, Chen Z, et al. Current status and etiology of valvular heart disease in China:a population-based survey[J].BMC Cardiovasc Disord, 2021, 21(1):339.
• [64] Wang YS, Wu BT, Li J, et al. Distribution patterns of valvular and vascular complications in bicuspid aortic valve[J].Int Heart J, 2020, 61(2):273-280.
• [65] Zhao L, Chen L, Yang T, et al. Birth prevalence of congenital heart disease in China, 1980-2019:a systematic review and meta-analysis of 617 studies[J]. Eur J Epidemiol, 2020, 35(7):631-642.
• [66]中国生物医学工程学会体外循环分会. 2020年中国心外科手术和体外循环数据白皮书[J].中国体外循环杂志，2021, 19(5):257-260.
• [67] Wu GX, Liu LW, Zhou ZY, et al. East asian-specifi c common variant in TNNI3 predisposes to hypertrophic cardiomyopathy[J].Circulation, 2020, 142(21):2086-2089.
• [68] Christensen AH, Platonov PG, Jensen HK, et al. Genotypephenotype correlation in arrhythmogenic right ventricular cardiomyopathy-risk of arrhythmias and heart failure[J]. J Med Genet, 2021.
• [69] Chen L, Rao M, Chen X, et al. A founder homozygous DSG2variant in East Asia results in ARVC with full penetrance and heart failure phenotype[J]. Int J Cardiol, 2019, 274:263-270.
• [70] Rao M, Guo G, Li M, et al. The homozygous variant c.245G>A/p. G82D in PNPLA2 is associated with arrhythmogenic cardiomyopathy phenotypic manifestations[J]. Clin Genet,2019, 96(6):532-540.
• [71] Hao G, Wang X, Chen Z, et al. Prevalence of heart failure and left ventricular dysfunction in China:the China Hypertension Survey, 2012-2015[J]. Eur J Heart Fail, 2019, 21(11):1329-1337.
• [72] Zhang YH, Zhang J, Butler J, et al. Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China:results from the China Heart Failure(China-HF)Registry[J]. J Card Fail, 2017,23(12):868-875
• [73]国家心血管病医疗质量控制中心专家委员会心力衰竭专家工作组. 2020中国心力衰竭医疗质量控制报告[J].中国循环杂志，2021, 36(3):221-238.
• [74] Li Y, Sun XL, Qiu H, et al. Long-term outcomes a n d independent predictors of mortality in patients presenting to emergency departments with acute heart failure in Beijing:a multicenter cohort study with a 5-year follow-up[J]. Chin Med J(Engl), 2021, 134(15):1803-1811.
• [75] Li M, Wang Q, Zhao J, et al. Chinese SLE Treatment and Research group(CSTAR)registry:II. prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus[J]. Lupus, 2014, 23(10):1085-1091.
• [76] Zhang R, Dai LZ, Xie WP, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era[J].Chest, 2011, 140(2):301-309.
• [77] Zhang Z, Lei J, Shao X, et al. Trends in hospitalization and inhospital mortality from VTE, 2007 to 2016, in China[J].Chest, 2019, 155(2):342-353.
• [78] Zhai Z, Wang D, Lei J, et al. Trends in risk stratifi cation,in-hospital management and mortality of patients with acute pulmonary embolism:an analysis from the China pulmonary thromboembolism registry study(CURES)[J]. Eur Respir J, 2021, 58(4):2002963.
• [79] Zhai ZG, Kan QC, Li WM, et al. VTE risk profiles and prophylaxis in medical and surgical inpatients:the identifi cation of Chinese hospitalized patients’ risk profile for venous thromboembolism(DissolVE-2)-A cross-sectional study[J].Chest, 2019, 155(1):114-122.
• [80] Li K, Zhang KW, Li TX, et al. Primary results of abdominal aortic aneurysm screening in the at-risk residents in middle China[J]. BMC Cardiovasc Disord, 2018, 18(1):60.
• [81]姜波，李馨桐，张东明，等.中国东北地区腹主动脉瘤超声筛查初步结果[J].中华血管外科杂志，2019, 4(1):20-24.
• [82] Wang ZW, Wang X, Hao G, et al. A national study of the prevalence and risk factors associated with peripheral arterial disease from China:the China hypertension survey, 2012-2015[J].Int J Cardiol, 2019, 275:165-170.
• [83] Hua Y, Jia L, Xing Y, et al. Distribution pattern of atherosclerotic stenosis in Chinese patients with stroke:a multicenter registry study[J].Aging Dis, 2019, 10(1):62-70.
• [84]《中国脑卒中防治报告》编写组.《中国脑卒中防治报告2019》概要[J].中国脑血管病杂志，2020,17(5):272-281.
• [85] Xiong HL, Peng M, Jiang XJ, et al. Time trends regarding the etiology of renal artery stenosis:18 years’ experience from the China Center for Cardiovascular Disease[J]. J Clin Hypertens(Greenwich), 2018, 20(9):1302-1309.
• [86]车武强，蒋雄京，董徽，等.锁骨下动脉狭窄的病因和解剖特征：阜外医院18年1793例患者分析[J].中国循环杂志，2018, 33(12):1197-1202.
• [87] Liu D, Ma ZQ, Yang JG, et al. Prevalence and prognosis significance of cardiovascular disease in cancer patients:a population-based study[J]. Aging(Albany NY), 2019,11(18):7948-7960.
• [88] Zhang Z, Pack Q, Squires RW, et al. Availability and characteristics of cardiac rehabilitation programmes in China[J].Heart Asia, 2016, 8(2):9-12.
• [89] Li J, Li LSW. Development of rehabilitation in China[J]. Phys Med Rehabil Clin N Am, 2019, 30(4):769-773.
• [90]张娜，张元鸣飞，刘京宇，等.国家康复医学专业医疗服务与质量安全报告（2019年）[J].中华物理医学与康复杂志，2020, 42(12):1146-1152.
• [91]国家心血管病中心.中国心血管健康与疾病报告2021[M].北京：科学出版社，2022.